TWI789331B - Cancer vaccine composition and kit - Google Patents

Abstract

The present disclosure relates to a cancer vaccine composition and a kit which contain a natural extract as an active ingredient. A composition according to an aspect of the present disclosure, which contains a ginseng berry extract, activates the immune function of the human body and is useful in treating cancer. A composition according to another aspect of the present disclosure, which further contains ovalbumin in addition to the ginseng berry extract, exhibits remarkable effect in preventing, improving and treating cancer due to a maximized synergic effect of the two ingredients. Because the immune mechanism of the body is used, cancer can be treated without the side effects of the existing anticancer drug therapy and radiation therapy.

Description

Cancer Vaccine Compositions and Kits

The present disclosure relates to cancer vaccine compositions and kits containing natural extracts as active ingredients.

Recently, the term immunity has frequently appeared in the treatment of various diseases. The immune system pervades the body. The immune system defends against the invasion of microorganisms or pathogens from the outside, and eliminates these pathogens once they enter the body.

Recently, "immunity" is also mentioned in the treatment of cancer. The most desired anticancer therapy is to selectively kill cancer cells without destroying normal cells. However, previously known anticancer drug therapy or radiation therapy cannot avoid damage to normal tissue to some extent. Research is being conducted on treatments that use the body's immune mechanism, one of the defense systems to fight disease with minimal side effects, to eliminate cancer cells.

(Non-Patent Document 1) Topalian SL et al., J Clin Oncol 1988; 6: 839-53.

In one aspect, the present disclosure relates to providing compositions that have a synergistic effect in the treatment of cancer.

In one aspect, the present disclosure provides a cancer vaccine composition comprising ginseng berry extract as an active ingredient.

In another aspect, the present disclosure provides a composition for promoting proliferation of bone marrow cells, the composition comprising ginseng berry extract as an active ingredient.

In another aspect, the present disclosure provides a composition for activating dendritic cells comprising ginseng berry extract as an active ingredient.

In another aspect, the present disclosure provides a composition for promoting activation of T cells, the composition comprising ginseng berry extract as an active ingredient.

In another aspect, the disclosure provides a kit comprising: a composition comprising ovalbumin; a composition comprising ginseng berry extract; and instructions, wherein the instructions describe the composition comprising ovalbumin and Simultaneous administration method of composition containing ginseng berry extract.

A composition containing ginseng berry extract according to an aspect of the present disclosure is suitable for treating cancer because the composition activates the immune function of the human body. According to another aspect of the disclosure, the composition further containing ovalbumin in addition to the ginseng berry extract is effective in preventing, improving and cancer treatment, which is attributed to the maximized synergistic effect of the two components. Because the body's immune mechanisms are used, cancer can be treated without the side effects of existing anticancer drug therapies and radiation therapy.

Figures 1a and 1b show bone marrow cell proliferation 24 hours after treatment with 100 g/mL ginseng root extract (ginseng root; GR) or ginseng berry extract (ginseng berry; GB).

Figure 2 shows the number of CD11c ⁺ dendritic cells determined by FACS 24 hours after intravenous injection of 10 mg/kg or 50 mg/kg ginseng berry extract to 6-week-old mice.

Figure 3 shows the numbers of IFN-γ and TNF-α producing helper T cells and killer T cells measured after intravenous injection of 50 mg/kg ginseng berry extract to 6-week-old mice twice at 3-day intervals.

Figure 4 shows the increase in antigen presentation capacity of dendritic cells measured after administration of ovalbumin (OVA) alone or ovalbumin and ginseng berry extract (OVA+GB).

Figure 5 shows the proliferation of antigen-specific T cells measured after administration of ovalbumin (OVA) alone or ovalbumin and ginseng berry extract (OVA+GB).

FIG. 6 shows tumor volumes measured after administration of ovalbumin (OVA) alone or ovalbumin and ginseng berry extract (OVA+GB) to tumor-implanted mice.

Hereinafter, the present disclosure is described in detail.

In one aspect, the present disclosure provides a cancer vaccine composition comprising ginseng berry extract as an active ingredient.

In one aspect, the present disclosure provides a method for improving the body's immune function against cancer, the method comprising the step of: administering ginseng berry extract to a subject in need thereof.

In one aspect, the present disclosure provides the use of ginseng berry extract for improving the immune function of the body against cancer.

In one aspect, the present disclosure provides the use of ginseng berry extract in the preparation of a composition for improving the immune function of the body against cancer.

In this disclosure, a "cancer vaccine" may refer to a substance used in active immunotherapy, in which the body's immune function is activated by administering cancer-specific antigens of cancer cells to a cancer patient, thereby attacking cancer cells and eliminating the cancer.

In this disclosure, "cancer" may refer to a disease in which a mass of undifferentiated cells or a tumor grows indefinitely in a tissue. Due to their unregulated growth, abnormal cells can invade tissues and nearby organs, forming masses and destroying or altering existing structures. finally, These cells can cause death as they destroy nearby normal tissues or organs and spread to other organs. Examples of cancers include, but are not limited to, the following cancers: brain and spinal cord tumors, head and neck cancer, lung cancer, breast cancer, thymoma, mesothelioma, esophagus cancer, stomach cancer, colon cancer, liver cancer, pancreatic cancer, bile duct cancer, kidney cancer, Bladder cancer, prostate cancer, testicular cancer, germ cell tumors, ovarian cancer, cervical cancer, endometrial cancer, lymphoma, acute leukemia, chronic leukemia, multiple myeloma, sarcoma, malignant melanoma and skin cancer.

In one aspect, the present disclosure provides a composition for promoting proliferation of bone marrow cells, the composition comprising ginseng berry extract as an active ingredient.

In one aspect, the present disclosure provides a method for promoting proliferation of bone marrow cells, the method comprising the step of: administering ginseng berry extract to a subject in need thereof.

In one aspect, the present disclosure provides the use of ginseng berry extract for promoting proliferation of bone marrow cells.

In one aspect, the present disclosure provides the use of ginseng berry extract in the preparation of a composition for promoting proliferation of bone marrow cells.

In another aspect, the present disclosure provides a composition for activating dendritic cells comprising ginseng berry extract as an active ingredient.

In one aspect, the present disclosure provides a method for activating dendritic cells, the method comprising the step of: administering ginseng berry extract to a subject in need thereof.

In one aspect, the present disclosure provides the use of ginseng berry extract in activating dendritic cells.

In one aspect, the present disclosure provides the use of ginseng berry extract in the preparation of a composition for activating dendritic cells.

In another aspect, the present disclosure provides a composition for promoting activation of T cells, the composition comprising ginseng berry extract as an active ingredient.

In one aspect, the present disclosure provides a method for promoting activation of T cells, the method comprising the step of: administering ginseng berry extract to a subject in need thereof.

In one aspect, the present disclosure provides the use of ginseng berry extract in promoting the activation of T cells.

In one aspect, the present disclosure provides the use of ginseng berry extract in the preparation of a composition for promoting the activation of T cells.

T cells may include killer T cells, helper T cells, regulatory T cells and memory T cells.

In the present disclosure, "ginseng" can be Korean ginseng or ginseng ( Panax ginseng ).

In this disclosure, "extract" includes any substance extracted from a natural product, regardless of extraction method, extraction solvent, extracted component or type of extract. The term is used in a broad sense and includes substances obtained by otherwise processing or treating the obtained extract. In particular, processing or treatment may be fermentation or enzymatic treatment of the extract. Thus, in the present disclosure, extracts include fermentation products, concentrated shrinkage and drying products. In particular, extracts in the present disclosure may be fermentation products.

In the present disclosure, "ginseng berry" may mean the fruit of ginseng. Specifically, it may mean the fruits of 3 to 5 year old ginseng, more specifically 4 year old ginseng, which ripen for about a week in July. Ginseng berries for use in the present disclosure are not limited by how they are obtained. Ginseng can be cultivated or purchased commercially.

Ginseng berries of the present disclosure contain more mineral components, including vitamins and ginsenosides, than ginseng roots commonly used in the art. Specifically, ginseng berries and ginseng roots are completely different in composition of ginsenosides. More specifically, ginseng berries can exhibit significantly better effects than ginseng roots because they contain more Protopanaxatriol (PT)-based ginsenosides including ginsenosides Re, Rg1, Rg2 and the like.

In this disclosure, "ginseng berry extract" includes any substance extracted from ginseng berries, regardless of extraction method, extraction solvent, extracted component or type of extract. It includes substances that can be extracted by treating them with heat, acid, alkali, enzymes, etc., and this term is used in a broad sense including substances that can be obtained by processing or treating the obtained extracts in other ways. Specifically, the processing or treatment may be fermentation or enzymatic treatment of ginseng berry extract. Therefore, in the present disclosure, the ginseng berry extract may be a fermentation product. Furthermore, in this disclosure, people The ginseng berry extract may specifically be an extract of live ginseng berries or an extract of dried ginseng berries. In the present disclosure, live ginseng berries, dried ginseng berries, or other processed products of ginseng berries (eg, fermented products, ground dried products, etc.) may be similar or identical in composition. Thus, compositionally similar or identical live ginseng berries, dried ginseng berries, or other processed products of ginseng berries may exhibit the same effects intended by the present disclosure.

In the present disclosure, the ginseng berry extract can be obtained by heating extraction, cold extraction, reflux condensation extraction, ultrasonic extraction and the like. However, extraction methods apparent to those skilled in the art may be used without limitation. The ginseng berries used to prepare the ginseng berry extract of the present disclosure may be dried ginseng berries, live ginseng berries, ginseng berry powder, and the like. Any substance prepared from live ginseng berries may be used without limitation. The ginseng berry extract of the present disclosure can be a C ₁ -C ₆ alcoholic extract of ginseng berry, specifically an ethanolic extract of ginseng berry. More specifically, the ginseng berry extract of the present disclosure may be an extract obtained by adding C ₁ -C ₆ alcohols, specifically ethanol, to extract ginseng berries. The ginseng berry extract of the present disclosure also includes a ginseng berry extract obtained by concentrating an extract obtained by extraction with ethanol under reduced pressure. Specifically, concentration under reduced pressure may be performed at 35-50° C., but is not limited thereto. The excellent synergistic effect of the various components in the ginseng berry extract of the present disclosure is achieved when concentration under reduced pressure is performed in the above temperature range. In this aspect, concentration under reduced pressure may specifically be at or above 36°C, 37°C or above 37°C, 38°C or above 38°C, 39°C or above 39°C, 40°C or above 40°C, 41°C or above 41°C, or 42°C or above 42°C and/or at or below 49°C, 48°C or below 48°C, 47°C or below 47°C, 46°C or lower, 45°C or lower, 44°C or lower, or 43°C or lower. Further, concentration under reduced pressure may be specifically at 600 mmHg or higher, 620 mmHg or higher, 640 mmHg or higher, 650 mmHg or higher, 660 mmHg or higher, 680 mmHg or higher, 700 mmHg or higher, 720 mmHg or higher High or at 740mmHg or more, and/or at 760mmHg or less, 740mmHg or less, 720mmHg or less, 700mmHg or less, 680mmHg or less, 660mmHg or less, 650mmHg or less, 640mmHg or more Low, 620mmHg or lower, or 600mmHg or lower.

In one aspect of the present disclosure, the ginseng berry extract can be obtained by: 1) by drying live ginseng (ginseng) ( Panax ginseng CA Meyer) by sun drying or hot air drying after removing the seeds pulp and skin of the fruit to prepare dried ginseng berries; and 2) extraction and drying at room temperature by adding water or an organic solvent (especially ethanol) and then concentrating under reduced pressure at 40-45° C. and 600-700 mmHg Ginseng berries.

The ginsenoside berry extract of the present disclosure may contain ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rc, ginsenoside Rd, ginsenoside Re, ginsenoside Rg1 or ginsenoside Rg2. However, since the ginseng berry extract of the present disclosure contains Various substances including vitamins, minerals, and anthocyanins other than ginsenosides, the effect of the composition according to an aspect of the present disclosure is derived from the synergistic effect of various substances, rather than from a single ginsenoside or ginsenoside combination (for example, saponin).

In one aspect, the composition may further contain albumin as an active ingredient. The concentration of albumin may be 0.001-0.1 μg/mL. Specifically, the concentration may be 0.0009 μg/mL or higher, 0.001 μg/mL or higher, 0.005 μg/mL or higher, 0.007 μg/mL or higher, 0.009 μg/mL or higher, 0.01 μg/mL or higher, mL or higher, 0.013 μg/mL or higher, 0.015 μg/mL or higher, 0.02 μg/mL or higher, 0.03 μg/mL or higher, 0.04 μg/mL or higher, 0.045 μg/mL or Higher, 0.05 μg/mL or higher, 0.051 μg/mL or higher, 0.055 μg/mL or higher, 0.06 μg/mL or higher, 0.065 μg/mL or higher, 0.07 μg/mL or higher , 0.08 μg/mL or greater, 0.09 μg/mL or greater, 0.095 μg/mL or greater, 0.099 μg/mL or greater, 0.1 μg/mL or greater, or 0.11 μg/mL or greater, and 0.12 μg/mL or less, 0.11 μg/mL or less, 0.1 μg/mL or less, 0.09 μg/mL or less, 0.08 μg/mL or less, 0.07 μg/mL or less, 0.06 μg /mL or less, 0.05 μg/mL or less, 0.04 μg/mL or less, 0.03 μg/mL or less, 0.02 μg/mL or less, 0.01 μg/mL or less, 0.009 μg/mL or lower, 0.005 μg/mL or lower, 0.004 μg/mL or lower, 0.003 μg/mL or less, 0.002 μg/mL or less, 0.001 μg/mL or less, or 0.0009 μg/mL or less.

Albumin may be ovalbumin. In this disclosure, ovalbumin refers to protein present in albumen, which also contains sugars, phosphates, etc. in addition to amino acids, etc. Because the effect of the composition according to an aspect of the present disclosure is derived from the synergistic effect of the combination of various substances contained in the ginseng berry extract and albumin (for example, ovalbumin), that is, compared to when only ginseng When the berry extract is used, it can achieve better effects in the improvement, prevention and treatment of cancer.

The composition according to one aspect of the present disclosure may contain 0.001-80.0 wt% of ginseng berry extract based on the total weight of the composition. Specifically, the composition according to one aspect of the present disclosure may contain 0.0005 wt % or more, 0.0007 wt % or more, 0.0009 wt % or more, 0.001 wt % or more, based on the total weight of the composition Large, 0.003wt% or more, 0.005wt% or more, 0.007wt% or more, 0.009wt% or more, 0.01wt% or more, 0.05wt% or more, 0.1wt% or more , 1wt% or more, 5wt% or more, 10wt% or more, 15wt% or more, 20wt% or more, 30wt% or more, 40wt% or more, 45wt% or more, 50wt % or more, 55wt% or more, 60wt% or more, 65wt% or more, 70wt% or more, 75wt% or more, 80wt% or more, 85wt% or more or 90wt% or Greater, or 99wt% or less, 90wt% or less, 80wt% or less, 75wt% or less, 65wt% or less, 60wt% or less, 55wt% or less, 50wt% or less, 45wt% or less, 40wt% or less, 30wt% or less, 20wt% or less, 10wt% or less, 5wt% or less, 1wt% or less, 0.1wt% or less, 0.05wt% or less, 0.03wt% or less, 0.01wt% or less, 0.008wt% or less, 0.006wt% or less, 0.004wt% or Less, 0.002 wt% or less, 0.001 wt% or less, or 0.0005 wt% or less of ginseng berry extract.

In this aspect, the concentration of ginseng berry extract may be 1-100 μg/mL. Specifically, the concentration may be 0.5 μg/mL or higher, 0.9 μg/mL or higher, 1.0 μg/mL or higher, 5 μg/mL or higher, 10 μg/mL or higher, 15 μg/mL or higher High, 20 μg/mL or higher, 30 μg/mL or higher, 40 μg/mL or higher, 45 μg/mL or higher, 48 μg/mL or higher, 49 μg/mL or higher, 50 μg/mL or higher , 51 μg/mL or higher, 52 μg/mL or higher, 55 μg/mL or higher, 60 μg/mL or higher, 70 μg/mL or higher, 80 μg/mL or higher, 90 μg/mL or higher, 100 μg/mL or more, 101 μg/mL or more, or 105 μg/mL or more, and may be 106 μg/mL or less, 101 μg/mL or less, 96 μg/mL or less, 91 μg/mL or more Low, 81 μg/mL or less, 71 μg/mL or less, 61 μg/mL or less, 56 μg/mL or less, 53 μg/mL or less, 52 μg/mL or less, 51 μg/mL or less , 50 μg/mL or less, 49 μg/mL or less, 48 μg/mL or less, 45 μg/mL or less, 40 μg/mL or less, 30 μg/mL or less, 20 μg/mL or less, 10 μg/mL or less, 9 μg/mL or less, 7 μg/mL or less, 5 μg/mL or less, 3 μg/mL or less, 1 μg/mL or less, 0.9 μg/mL or less, 0.7 μg/mL or less or 0.5 μg/mL or less.

Ginsenosides contained in the ginseng berry extract of the present disclosure may consist of: ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rc, ginsenoside Rd, ginsenoside Re, ginsenoside Rg1 or ginsenoside Rg2.

In one aspect of the present disclosure, the ginseng berry extract may contain 0.1-10 wt% of each of the following items based on the total weight of the ginseng berry extract: ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rb3 , ginsenoside Rc, ginsenoside Rd, ginsenoside Rg1 or ginsenoside Rg2.

Specifically, the ginseng berry extract of the present disclosure may contain 1.3-3.3 wt% of ginsenoside Rb1 based on the total weight of the ginseng berry extract. The excellent synergistic effect of various components in the ginseng berry extract of the present disclosure is achieved within the above range. In this aspect, the ginseng berry extract of the present disclosure may contain 1.4 wt% or greater, 1.5 wt% or greater, 1.6 wt% or greater, 1.7 wt% or greater or 1.8 wt% or greater And/or 3.2wt% or less, 3.1wt% or less, 3.0wt% or less, 2.9wt% or less or 2.8wt% or less ginsenoside Rb1.

Specifically, the ginseng berry extract of the present disclosure may contain 1.5-3.5 wt% of ginseng berry extract based on the total weight of the ginseng berry extract Ginsenoside Rb2. The excellent synergistic effect of various components in the ginseng berry extract of the present disclosure is achieved within the above range. In this aspect, the ginseng berry extract of the present disclosure may contain 1.6 wt% or greater, 1.7 wt% or greater, 1.8 wt% or greater, 1.9 wt% or greater or 2.0 wt% or greater And/or 3.4wt% or less, 3.3wt% or less, 3.2wt% or less, 3.1wt% or less or 3.0wt% or less ginsenoside Rb2.

Specifically, the ginseng berry extract of the present disclosure may contain 0.2-1.2 wt% of ginsenoside Rb3 based on the total weight of the ginseng berry extract. The excellent synergistic effect of various components in the ginseng berry extract of the present disclosure is achieved within the above range. In this aspect, the ginseng berry extract of the present disclosure may contain 0.2 wt% or greater, 0.3 wt% or greater, 0.4 wt% or greater, 0.5 wt% or greater, 0.6 wt% or greater or 0.7wt% or more and/or 1.5wt% or less, 1.4wt% or less, 1.3wt% or less, 1.2wt% or less, 1.1wt% or less, 1.0wt% or less Little or 0.9wt% or less ginsenoside Rb3.

Specifically, the ginseng berry extract of the present disclosure may contain 2.7-4.7 wt% of ginsenoside Rc based on the total weight of the ginseng berry extract. The excellent synergistic effect of various components in the ginseng berry extract of the present disclosure is achieved within the above range. In this aspect, the ginseng berry extract of the present disclosure may contain 2.8 wt% or greater, 2.9 wt% or greater, 3.0 wt% or greater, 3.1 wt% or greater or 3.2 wt% or greater and/or 4.7wt% or less, 4.6wt% or less, 4.5 wt% or less, 4.4 wt% or less, or 4.3 wt% or less of ginsenoside Rc.

Specifically, the ginseng berry extract of the present disclosure may contain 3.8-5.8 wt% of ginsenoside Rd based on the total weight of the ginseng berry extract. The excellent synergistic effect of various components in the ginseng berry extract of the present disclosure is achieved within the above range. In this aspect, the ginseng berry extract of the present disclosure may contain 3.9 wt% or greater, 4.0 wt% or greater, 4.1 wt% or greater, 4.2 wt% or greater or 4.3 wt% or greater And/or 5.7wt% or less, 5.6wt% or less, 5.5wt% or less, 5.4wt% or less or 5.3wt% or less ginsenoside Rd.

Specifically, the ginseng berry extract of the present disclosure may contain 8.0-30.0 wt% of ginsenoside Re based on the total weight of the ginseng berry extract. The excellent synergistic effect of various components in the ginseng berry extract of the present disclosure is achieved within the above range. In this aspect, the ginseng berry extract of the present disclosure may contain 8.0 wt% or greater, 8.5 wt% or greater, 9.0 wt% or greater, 9.5 wt% or greater, 10.0 wt% or greater , 10.5wt% or more, 11.0wt% or more, 11.5wt% or more, 12.0wt% or more, 12.5wt% or more, 12.6wt% or more, 12.7wt% or more, 12.8wt% or more, 12.9wt% or more, 13.0wt% or more, 13.1wt% or more, 13.2wt% or more, 13.3wt% or more, 13.4wt% or more, 13.5 wt% or more, 13.6wt% or more, 13.7wt% or more, 13.8wt% or more, 13.9wt% or greater, 14.0 wt% or greater, 15 wt% or greater, 20 wt% or greater, or 25 wt% or greater, and/or 30 wt% or less, 25 wt% or less, 20 wt% or less, 19.0wt% or less, 18.5wt% or less, 18.0wt% or less, 17.5wt% or less, 17.0wt% or less, 16.5wt% or less, 16.4wt% or less, 16.3 wt% or less, 16.2wt% or less, 16.1wt% or less, 16.0wt% or less, 15.9wt% or less, 15.8wt% or less, 15.7wt% or less, 15.6wt % or less, 15.5wt% or less, 15.4wt% or less, 15.3wt% or less, 15.2wt% or less, 15.1wt% or less or 15.0wt% or less .

Specifically, the ginseng berry extract of the present disclosure may contain 2.2-4.2 wt% of ginsenoside Rg1 based on the total weight of the ginseng berry extract. The excellent synergistic effect of various components in the ginseng berry extract of the present disclosure is achieved within the above range. In this aspect, the ginseng berry extract of the present disclosure may contain 2.3 wt% or greater, 2.4 wt% or greater, 2.5 wt% or greater, 2.6 wt% or greater or 2.7 wt% or greater And/or 4.3wt% or less, 4.2wt% or less, 4.1wt% or less, 4.0wt% or less or 3.9wt% or less ginsenoside Rg1.

Specifically, the ginseng berry extract of the present disclosure may contain 0.5-2.5 wt% of ginsenoside Rg2 based on the total weight of the ginseng berry extract. The excellent synergistic effect of various components in the ginseng berry extract of the present disclosure is achieved within the above range. In this form, the disclosure 0.6wt% or greater, 0.7wt% or greater, 0.8wt% or greater, 0.9wt% or greater or 1.0wt% or greater and/or 2.4wt% or less , 2.3wt% or less, 2.2wt% or less, 2.1wt% or less or 2.0wt% or less ginsenoside Rg2.

Accordingly, the ginseng berry extract of the present disclosure may contain 23.0-80.0 wt% total ginsenosides based on the total weight of the ginseng berry extract. The excellent synergistic effect of various components in the ginseng berry extract of the present disclosure is achieved within the above range. In the present disclosure, total ginsenosides may mean all ginsenoside components present in ginseng berry extract. For example, total ginsenosides may mean the sum of ginsenosides Rb1, Rb2, Rb3, Rc, Rd, Re, Rg1, and Rg2.

In this aspect, the ginseng berry extract of the present disclosure may contain 23.0 wt% or greater, 24.0 wt% or greater, 25.0 wt% or greater, 25.5 wt% or Greater, 26.0 wt% or greater, 26.5 wt% or greater, 27 wt% or greater, 27.5 wt% or greater, 28.0 wt% or greater, 28.5 wt% or greater, 29.0 wt% or greater , 29.5wt% or more, 30.0wt% or more, 30.5wt% or more, 31.0wt% or more, 31.5wt% or more, 32.0wt% or more, 35wt% or more, 40wt % or more, 45wt% or more, 50wt% or more, 55wt% or more, 60wt% or more, 65wt% or more, 70wt% or more, 75wt% or more or 80wt% or Greater, and/or 80wt% or less, 75wt% or less, 70wt% or less Small, 65wt% or less, 60wt% or less, 55wt% or less, 50wt% or less, 45wt% or less, 41.0wt% or less, 40.5wt% or less, 40wt% or less Small, 39.5wt% or less, 39wt% or less, 38.5wt% or less, 38wt% or less, 37.5wt% or less, 37wt% or less, 36.5wt% or less, 36wt% or less, 35.5wt% or less, 35.0wt% or less, 34.5wt% or less or 34.0wt% or less ginsenosides.

Ginseng berry extracts of the present disclosure may have 0.5-2.5 protopanaxadiol (PD)-based ginsenosides (Rb1, Rb2, Rc, and Rd) and protopanaxatriol (PT)-based ginsenosides (Re, Rg1 and Rg2) is the ratio of PD/PT. The excellent synergistic effect of the various components in the ginseng berry extract of the present disclosure is achieved in the above temperature range. In this aspect, the ginseng berry extract of the present disclosure may have the following ratio of PD ginsenosides to PT ginsenosides, PD/PT: 0.1 or greater, 0.15 or greater, 0.2 or greater, 0.25 or greater , 0.3 or greater, 0.35 or greater, 0.4 or greater, 0.45 or greater, 0.5 or greater, 0.55 or greater, 0.6 or greater, 0.61 or greater, 0.62 or greater, 0.63 or greater , 0.64 or greater, 0.65 or greater, 0.69 or greater, 0.7 or greater, 0.73 or greater, 0.75 or greater, 0.8 or greater, 0.85 or greater, 0.9 or greater, 0.95 or greater , 1.0 or greater, 1.1 or greater, 1.3 or greater, 1.5 or greater, 1.7 or greater, 1.9 or greater, 2.1 or greater, 2.3 or greater, 2.5 or greater, or 2.6 or greater Greater, and 2.7 or less, 2.5 or less, 2.4 or less, 2.2 or less, 2.0 or less, 1.8 or less, 1.7 or less, 1.5 or less, 1.3 or less, 1.25 or less, 1.24 or less, 1.23 or less, 1.22 or less, 1.21 or less, 1.20 or less, 1.05 or less, 1.0 or less, 0.95 or less, 0.9 or less, 0.85 or less, 0.8 or less, 0.75 or less, 0.73 or less, 0.7 or less, 0.69 or less, 0.65 or less, 0.6 or less, 0.55 or less, 0.5 or less, 0.45 or less, 0.4 or less, 0.3 or less, 0.2 or less, or 0.1 or less. Specifically, the ginseng berry extract of the present disclosure may have the following ratio of PD ginsenosides to PT ginsenosides, PD/PT: 0.55-2.45, 0.6-2.4, 0.65-2.35, or 0.7-2.3.

In one aspect of the present disclosure, the ginseng berry extract may further contain vitamins, minerals and anthocyanins.

In an aspect of the present disclosure, the minerals may include one or more of the following based on the total weight of the ginseng berry extract: 4000 mg/100 g or greater potassium, 600 mg/100 g or greater calcium, 40 mg/100 g or greater iron, 150mg/100g or greater phosphorus, 250mg/100g or greater magnesium, and 140mg/100g or greater zinc.

In one aspect of the present disclosure, the ginseng berry extract may contain 4000mg/100g to 10g/100g of potassium, 600mg/100g to 5g/100g of calcium, 40mg/100g to 1g/100g of iron, 150mg/100g to 1g/100g of phosphorus, 250mg/100 g to 5g/100g of magnesium and 140mg/100g to 5g/100g of zinc, but not limited thereto.

In an aspect of the present disclosure, the vitamins may include one or more of the following based on the total weight of the ginseng berry extract: 150 μg/100 g or greater vitamin A, 8 mg/100 g or greater vitamin B ₁ , 5 mg Vitamin _B2 /100g or greater, vitamin B6 8mg/100g or greater, vitamin C _3mg /100g or greater, vitamin K 180μg/100g or greater, smoke 3.5mg/100g or greater Acid, 4mg/100g or greater pantothenic acid and 250μg/100g or greater folic acid.

In one aspect of the present disclosure, the ginseng berry extract may contain 150μg/100g to 20mg/100g vitamin A, 8mg/100g to 5g/100g vitamin _B1 , 5mg/100g to 5g/100g vitamin _B2 , Vitamin B ₆ from 8mg/100g to 5g/100g, Vitamin C from 3mg/100g to 5g/100g, Vitamin K from 180μg/100g to 20mg/100g, Niacin from 3.5mg/100g to 5g/100g, 4mg/100g Up to 5g/100g of pantothenic acid and 250μg/100g to 20mg/100g of folic acid, but not limited thereto.

In addition, the ginseng berry extract of the present disclosure may contain one or more compounds selected from the group consisting of anthocyanin compounds, their derivatives and their salts. Specifically, the anthocyanin compound may be selected from the group consisting of mallow chloride chloride, ideain chloride chloride, geranium chloride and anthocyanin rhamnoside chloride.

In one aspect of the present disclosure, the ginseng berry extract may contain 8.0-16.0 ppm (w/w) of chlorinated mallow pigment, 1.0-5.0 ppm (w/w) based on the total weight of the ginseng berry extract. Chlorinated cyanidin galactoside, 6.0-12.0ppm (w/w) chlorinated geranium and 2.0-6.0ppm (w/w) chlorinated anthocyanin rhamnoside.

In one aspect of the present disclosure, the ginseng berry extract may contain 8.0 ppm (w/w) or more, 9.0 ppm (w/w) or more, 10.0 ppm ( w/w) or greater, 11.0ppm (w/w) or greater, 12.0ppm (w/w) or greater, 12.5.0ppm (w/w) or greater, 13.0ppm (w/w) or Greater, 14.0ppm(w/w) or greater, 15.0ppm(w/w) or greater, or 16.0ppm(w/w) or greater, and/or 16.0ppm(w/w) or less, 15.0ppm(w/w) or less, 14.0ppm(w/w) or less, 13.0ppm(w/w) or less, 12.5ppm(w/w) or less, 12.0ppm(w/w) ) or less, 11.0 ppm (w/w) or less, 10.0 ppm (w/w) or less, 9.0 ppm (w/w) or less, or 8.0 ppm (w/w) or less chlorine Chemical mallow pigment.

In one aspect of the present disclosure, the ginseng berry extract may contain 0.1 ppm (w/w) or more, 1.0 ppm (w/w) or more, 2.0 ppm ( w/w) or greater, 2.2ppm (w/w) or greater, 2.4ppm (w/w) or greater, 2.5ppm (w/w) or greater, 3.0ppm (w/w) or greater Large, 4.0ppm(w/w) or greater or 5.0ppm(w/w) or greater, and/or 5.0ppm(w/w) or less, 4.0ppm(w/w) or less, 3.0ppm(w/w) or less, 2.5ppm(w/w) or less , 2.4ppm(w/w) or less, 2.2ppm(w/w) or less, 2.0ppm(w/w) or less, 1.0ppm(w/w) or less or 0.1ppm(w/w) w) or smaller chlorinated cyanidin galactosides.

In one aspect of the present disclosure, the ginseng berry extract may contain 6.0 ppm (w/w) or more, 7.0 ppm (w/w) or more, 7.5 ppm ( w/w) or greater, 8.0ppm (w/w) or greater, 8.5ppm (w/w) or greater, 9.0ppm (w/w) or greater, 10.0ppm (w/w) or greater Large, 11.0ppm(w/w) or greater or 12.0ppm(w/w) or greater, and/or 12.0ppm(w/w) or less, 11.0ppm(w/w) or less, 10.0 ppm(w/w) or less, 9.0ppm(w/w) or less, 8.5ppm(w/w) or less, 8.0ppm(w/w) or less, 7.5ppm(w/w) or less, 7.0 ppm (w/w) or less, or 6.0 ppm (w/w) or less geranium chloride.

In one aspect of the present disclosure, the ginseng berry extract may contain 2.0 ppm (w/w) or more, 2.5 ppm (w/w) or more, 3.0 ppm ( w/w) or greater, 3.5ppm (w/w) or greater, 4.0ppm (w/w) or greater, 5.0ppm (w/w) or greater, or 6.0ppm (w/w) or greater large, and/or 6.0ppm(w/w) or less, 5.0ppm(w/w) or less, 4.0ppm(w/w) or less, 3.5ppm(w/w) or less, 3.0ppm(w/w) or less, 2.5ppm(w/w) or less or 2.0ppm (w/w) or smaller chlorinated anthocyanin rhamnoglucoside.

In one aspect of the present disclosure, the composition may contain 0.01-1 part by weight of albumin based on 100 parts by weight of ginseng berry extract. Specifically, the composition may contain 0.001 parts by weight or more, 0.003 parts by weight or more, 0.005 parts by weight or more, 0.007 parts by weight or more, 0.009 parts by weight or more, 0.01 parts by weight or more, 0.03 parts by weight or more, 0.05 parts by weight or more, 0.07 parts by weight or more, 0.09 parts by weight or more, 0.1 parts by weight or more, 0.11 parts by weight or more, 0.12 parts by weight or more, 0.13 parts by weight Parts by weight or more, 0.13 parts by weight or more, 0.18 parts by weight or more, 0.2 parts by weight or more, 0.3 parts by weight or more, 0.4 parts by weight or more, 0.5 parts by weight or more, 0.6 parts by weight parts by weight or more, 0.7 parts by weight or more, 0.8 parts by weight or more, 0.9 parts by weight or more, 1.0 parts by weight or more, or 1.1 parts by weight or more and 1.05 parts by weight or less, 1.0 parts by weight or less, 0.9 parts by weight or less, 0.85 parts by weight or less, 0.75 parts by weight or less, 0.65 parts by weight or less, 0.55 parts by weight or less, 0.45 parts by weight or less, 0.35 parts by weight or Smaller, 0.25 parts by weight or less, 0.15 parts by weight or less, 0.13 parts by weight or less, 0.12 parts by weight or less, 0.11 parts by weight or less, 0.10 parts by weight or less, 0.09 parts by weight or less Small, 0.08 parts by weight or less, 0.07 parts by weight or less, 0.06 parts by weight or less, 0.05 parts by weight or less, 0.04 parts by weight or less, 0.03 parts by weight or less, 0.02 parts by weight or less, 0.01 parts by weight or less, 0.009 parts by weight or less, or 0.008 parts by weight or less of albumin.

In one aspect of the disclosure, the composition can be a pharmaceutical composition. The pharmaceutical composition according to an aspect of the present disclosure can be prepared as a solid, semi-solid or liquid formulation for oral administration or parenteral administration by adding inorganic or organic carriers.

Formulations for oral administration include tablets, pills, granules, soft or hard capsules, powders, granules, powders, emulsions, syrups, pellets and the like. Formulations for parenteral administration include injections, medical drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. Compositions according to one aspect of the present disclosure can be readily formulated according to common methods. Surfactants, excipients, colorants, fragrances, preservatives, stabilizers, buffers, suspending agents or another usual adjuvant may be used as appropriate.

The active ingredient contained in a composition according to an aspect of the present disclosure may be provided by mixing with a carrier, or encapsulated in a container-type carrier. When a diluent is used as a carrier, the diluent can be a solid, semi-solid or liquid material that can act as a carrier, excipient or medium for the active ingredient. Examples of suitable carriers, excipients or diluents include lactose, dextrose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, Water, methylparaben, propylparaben, talc, magnesium stearate or mineral oil. In another aspect of the present disclosure, the composition may further contain filler Agents, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, fungicides, etc.

Pharmaceutical compositions according to one aspect of the present disclosure may be provided as formulations that deliver the active ingredient in a rapid, sustained or delayed manner following administration to a mammal using methods well known in the art.

Pharmaceutical compositions according to an aspect of the present disclosure may be administered via various routes including, without limitation, oral, transdermal, subcutaneous, intravenous, intraperitoneal, intramuscular, topical or iontophoresis routes. In another aspect of the disclosure, the pharmaceutical composition can be administered topically or orally.

For mammals, the daily dosage of the active ingredient can usually be 1-2000mg/kg (body weight), more specifically 1-1800mg/kg (body weight), 1-1500mg/kg (body weight), 1-1000mg /kg (body weight), 1-800mg/kg (body weight), 1-600mg/kg (body weight), 1-400mg/kg (body weight), 1-200mg/kg (body weight), 1-100mg/kg (body weight) , 5-100 mg/kg (body weight) or 5-70 mg/kg (body weight) and can be administered once or several times a day. However, it should be understood that the actual dosage of the active ingredient can be determined by considering various relevant factors, such factors include the disease to be treated, the route of administration, the patient's age, sex and body weight, and the severity of the disease, etc., and the above-mentioned dosage is not based on Limit the scope of this disclosure in any way.

In another aspect of the disclosure, the composition can be a food composition. A food composition according to one aspect of the present disclosure includes Food additive composition or health food composition, and can be prepared as lozenges, hard capsules, soft capsules, pills, granules, beverages, meal bars, chocolate, caramel, confectionery, etc. using ingredients commonly used in this technology . In addition, the health food composition may further contain sufficient functional ingredients.

In another aspect, the disclosure provides a cancer vaccine kit comprising: a composition comprising albumin; a composition comprising ginseng berry extract; and instructions, wherein the instructions describe the composition comprising albumin And the simultaneous administration method of the composition containing the ginseng berry extract.

The dosage of the composition containing albumin can be 0.001-0.1 mg/kg/day, and the dosage of the composition containing ginseng berry extract can be 1-100 mg/kg/day. Specifically, the dosage of the composition containing albumin can be 0.0001 mg/kg/day or more, 0.0007 mg/kg/day or more, 0.0009 mg/kg/day or more, 0.001 mg/kg/day or more, day or greater, 0.003mg/kg/day or greater, 0.005mg/kg/day or greater, 0.007mg/kg/day or greater, 0.009mg/kg/day or greater, 0.01mg/kg/day day or greater, 0.015mg/kg/day or greater, 0.03mg/kg/day or greater, 0.05mg/kg/day or greater, 0.07mg/kg/day or greater, 0.08mg/kg/day or greater, 0.09 mg/kg/day or greater, 0.1 mg/kg/day or greater, or 0.11 mg/kg/day or greater, and 0.12 mg/kg/day or less, 0.1 mg/kg /day or less, 0.09mg/kg/day or less, 0.08mg/kg/day or less, 0.06mg/kg/day or less, 0.04mg/kg/day or less, 0.02 mg/kg/day or less, 0.01mg/kg/day or less, 0.008mg/kg/day or less, 0.006mg/kg/day or less, 0.004mg/kg/day or less, 0.002 mg/kg/day or less, 0.001 mg/kg/day or less, 0.0009 mg/kg/day or less, or 0.0008 mg/kg/day or less. In addition, the dosage of the composition containing ginseng berry extract can be 0.5 mg/kg/day or more, 0.7 mg/kg/day or more, 0.8 mg/kg/day or more, 0.9 mg/kg/day or more, day or greater, 1.0mg/kg/day or greater, 1.1mg/kg/day or greater, 5mg/kg/day or greater, 9mg/kg/day or greater, 10mg/kg/day or greater Large, 11 mg/kg/day or greater, 16 mg/kg/day or greater, 21 mg/kg/day or greater, 26 mg/kg/day or greater, 31 mg/kg/day or greater, 36 mg/kg /day or greater, 41mg/kg/day or greater, 46mg/kg/day or greater, 48mg/kg/day or greater, 49mg/kg/day or greater, 50mg/kg/day or greater , 51mg/kg/day or greater, 52mg/kg/day or greater, 57mg/kg/day or greater, 61mg/kg/day or greater, 66mg/kg/day or greater, 71mg/kg/day day or greater, 76mg/kg/day or greater, 81mg/kg/day or greater, 86mg/kg/day or greater, 91mg/kg/day or greater, 96mg/kg/day or greater, 98mg/kg/day or greater, 99mg/kg/day or greater, 100mg/kg/day or greater, or 101mg/kg/day or greater, and 102mg/kg/day or less, 101mg/kg/day day or less, 100mg/kg/day or less, 99mg/kg/day or less, 98mg/kg/day or less, 90mg/kg/day or less, 85mg/kg/day or less, 80mg/kg/day or more Small, 75mg/kg/day or less, 70mg/kg/day or less, 65mg/kg/day or less, 60mg/kg/day or less, 55mg/kg/day or less, 54mg/kg /day or less, 53mg/kg/day or less, 52mg/kg/day or less, 51mg/kg/day or less, 50mg/kg/day or less, 49mg/kg/day or less , 48mg/kg/day or less, 43mg/kg/day or less, 38mg/kg/day or less, 33mg/kg/day or less, 28mg/kg/day or less, 23mg/kg/day day or less, 18mg/kg/day or less, 15mg/kg/day or less, 13mg/kg/day or less, 12mg/kg/day or less, 11mg/kg/day or less, 10 mg/kg/day or less, 9 mg/kg/day or less, or 8 mg/kg/day or less.

In this aspect, the albumin may be ovalbumin.

In a kit according to an aspect of the present disclosure, the instructions may describe a second administration of the composition comprising albumin and the composition comprising ginseng berry extract 1-14 days after the first administration. Specifically, the second administration may be performed 1 day after, 2 days after, 3 days after, 4 days after, 5 days after, 6 days after, 7 days after, 8 days after, 9 days after, or 10 days after the first administration. 1 day, 11 days after, 12 days after, 13 days after, 14 days after, or 15 days after. The number of doses may vary depending on the target to be treated. Thus, administration may be performed only once or three or more times.

Hereinafter, the present disclosure will be described in detail through examples and test examples. However, the following examples and experimental examples are for illustration purposes only, and the scope of the present disclosure is not limited by these examples. In addition, in Various changes and modifications may be made by one of ordinary skill in the art without departing from the scope of the disclosure as defined by the appended claims.

[Example 1] Preparation of Ginseng Berry Extract Pretreatment of Ginseng Berries

Dried ginseng berries are prepared by sun-drying or hot-air drying the pulp and outer skin of live ginseng berries after removing the seeds.

Preparation of live ginseng berry extract

Crude ginseng berries are prepared by removing the seeds from the fruit of live ginseng (Panax ginseng C.A. Meyer) and mixing the juice, pulp and rind of the fruit. 30 g of ginseng berry extract was obtained from 1 kg of crude ginseng berries by adding 3 L of ethanol to reflux extraction at room temperature for 4 hours, filtering and then concentrating at 45° C. under reduced pressure.

[Comparative Example 1] Preparation of Ginseng Root Extract

A ginseng root extract was prepared in the same manner as in Example 1, except that the root of ginseng was used instead of the fruit of ginseng.

[Test Example 1] Comparison of Components Analysis of ginsenosides (ginsenosides) in ginseng berries and ginseng roots

After the oil-soluble components of the ginseng berry extract of Example 1 and the ginseng root extract of Comparative Example 1 were removed by treatment with ether, crude saponin was extracted with butanol (BuOH). After concentration, ginsenoside components were analyzed by HPLC. The results are shown in Figure 1 and Table 1.

It has been found that the ginseng berry extract according to the present disclosure contains a greater amount of total ginsenosides than the ginseng root extract, and in particular the composition of ginsenosides is quite different. Because the ginseng berry extract according to the present disclosure contains a larger amount of protopanaxadiol (PD) ginsenosides including ginsenosides Re, Rg1, Rg2, etc. than ginsenosides Rb1, Rb2, Rc, Rd, etc. Triol (protopanaxatriol; PT) ginsenoside, so it can be seen that the ginseng berry extract will exhibit a significantly superior effect than ginseng root.

Analysis of Mineral Components in Ginseng Berries and Ginseng Roots

Mineral components including vitamins in the ginseng berry extract of Example 1 and the ginseng root extract of Comparative Example 1 were analyzed. Analysis was performed according to the vitamin and mineral analysis method described in the Korean Food Standards Code to demonstrate that the properties of the ginseng berry extract of Example 1 as a "fruit" are different from those of the root part of ginseng.

[Table 2]

It has been found that ginseng berry extract according to the present disclosure contains more and various minerals than ginseng root extract. Therefore, it is expected to exhibit significantly superior effects than ginseng root.

Analysis of Anthocyanins in Ginseng Berry Extract

The anthocyanin components in the ginseng berry extract of Example 1 were quantitatively analyzed.

0.5 g of the ginseng berry extract of Example 1 was put into an amber flask. After adding 5 mL of 1% hydrochloric acid and shaking well, 10 mL of methanol was added. Subsequently, after being kept in the freezer for 12 hours and filtered, HPLC analysis was performed. Use Mightysil C18 (250 x 4.6, 5μm) and 2% formic acid in DIW (A) and 2% formic acid in ACN (B) as mobile phase, at 90% A->80% A, 20min->90% A , 25min->90% A, 30min under the conditions of performing HPLC (Waters) analysis. Results were analyzed using 520-nm UV.

Use anthocyanin kit (ExtraSynthese, France) (for detection of chlorinated mallow pigment), anthocyanin derivative kit Group (ExtraSynthese, France) (for the detection of chlorinated cyanidin galactoside and chlorinated anthocyanin rhamnoglucoside), standard chlorinated geranium and standard chlorinated morning glory for the quantitative analysis of anthocyanins in ginseng berries white. The results are shown in Table 3.

It has been found that ginseng berry extracts according to the present disclosure also contain high levels of various anthocyanins in addition to ginsenosides.

[Test Example 2] Effect of ginseng berry extract on proliferation of bone marrow cells Preparation of Experimental Animals

5-week-old C57BL/6, OT-1, OT-II TCR and C57BL/6-Lys5.1 (CD45.1) male mice weighing 18-22 g purchased from Central Lab Animal were habituated to Pacific Pharmaceuticals animals The lab environment lasted a week. During this period, the animals were housed in cages with sterile filter tops and were given ad libitum access to sterilized feed (normal diet (D12450B, Research Diets, New Brunswick, NJ, USA) and water. The experimental The chamber environment was maintained at 20±2°C and 50±10% humidity with a 12-hour light/dark cycle. Animals were maintained according to IACUC14-014.

Proliferation of bone marrow cells

After sacrificing mice by cervical dislocation, bone marrow cells (bone marrow nucleated cells) were cultured to 70% confluence in RPMI 1640 medium containing 10% bovine serum. After adding 50 ng/mL GM-CSF and IL-4 and culturing for 6 days, the cells were treated with ginseng root extract (GR) or ginseng berry extract (ginseng berry extract; GB) at a concentration of 50 μg/mL 24 hours. For FACS analysis, 0.5-1 million cells were resuspended in FACS buffer (2% FBS in PBS), and Fc receptors were blocked for 30 minutes. After adding fluorescently labeled antibodies that recognize CD86 and MHC class II, incubation was performed at 4°C for 30 minutes. Subsequently, after washing with FACS buffer, analysis was performed by flow cytometry (BD FACS LSR) using FlowJo (version 9.7.6) (Fig. 1).

[Test Example 3] Effect of ginseng berry extract on activation of spleen dendritic cells

After intravenous injection of 10 mg/kg or 50 mg/kg of the ginseng berry extract to the experimental animals of Test Example 2, the animals were sacrificed by cervical dislocation 24 hours later. After removing the spleen and adding collagenase containing 2% bovine serum, incubation was performed at room temperature for 20 minutes. After obtaining pellets by centrifugation of isolated cells and lysing the pellets after addition of Histopaque 1077 (Sigma-Aldrich), pellets were obtained by centrifugation again at 1700 g. Analysis was performed by flow cytometry (BD FACS LSR) using FlowJo (version 9.7.6) after addition of a fluorescently labeled antibody recognizing CD11c ⁺ and incubation for 30 minutes, followed by washing with FACS buffer. It was found that ginseng berry extract can promote the proliferation of splenic dendritic cells in a concentration-dependent manner (Fig. 2).

[Test Example 4] Effect of Ginseng Berry Extract on Activation of Helper T Cells and Killer T Cells

After intravenously injecting 50 mg/kg of the ginseng berry extract to the experimental animals of Test Example 2 twice at 3-day intervals, the animals were sacrificed by cervical dislocation 3 days after the second injection. After removing and weighing the spleen, a single cell suspension was prepared by triturating with a mixer. After filtering single cells with a cell strainer and removing RBCs using RBC lysis buffer or hypertonic solution, the lysate was completely removed using a cell strainer for FACS analysis. The total number of viable splenocytes was counted by staining with trypan blue. For FACS analysis, 0.5-1 million cells were resuspended in FACS buffer (2% FBS in PBS), and Fc receptors were blocked for 30 minutes. After addition of fluorescently labeled antibodies recognizing CD4, CD8 ^, IFN- and ^TNF- , incubation was performed at 4°C for 30 minutes. Subsequently, after washing with FACS buffer, analysis was performed by flow cytometry (BD FACS LSR) using FlowJo (version 9.7.6). The results are shown in Figure 3.

[Test Example 5] Effect of Ginseng Berry Extract on Improving Antigen Presentation Ability of Dendritic Cells

After intravenously injecting PBS, ovalbumin (ovalbumin; OVA) alone or 0.05 mg/kg ovalbumin and 50 mg/kg ginseng berry extract (ovalbumin and ginseng berry extract) to the experimental animals of Test Example 2 ; OVA+GB), animals were sacrificed by cervical dislocation. After removing the spleen and adding collagenase containing 2% bovine serum, incubation was performed at room temperature for 20 minutes. After obtaining pellets by centrifugation of isolated cells and lysing the pellets after addition of Histopaque 1077 (Sigma-Aldrich), pellets were obtained by centrifugation again at 1700 g. After adding fluorescently labeled antibodies that can recognize CD11c ⁺ , MHC I and MHC II and incubating for 30 minutes, followed by washing with FACS buffer, by flow cytometry using FlowJo (version 9.7.6) (BD FACS LSR) for analysis. It was found that the group co-administered with ginseng berry extract and ovalbumin exhibited increased antigen presentation ability of dendritic cells than the group administered with ovalbumin alone ( FIG. 4 ).

[Test Example 6] Effect of ginseng berry extract on promotion of proliferation of antigen-specific T cells

Among the experimental animals of Test Example 2, CD8 T cells were isolated from OT-I mice, and CD4 T cells were isolated from OT-II mice. Cells were stained by dissolving in PBS (Invitrogen) containing 10 gM CFSE. After implanting cells into CD45.1 mice and then intravenously injecting PBS, 0.05 mg/kg of ovalbumin (OVA) alone or 0.05 mg/kg of ovalbumin and 50 mg/kg of ginseng berry extract ( ovalbumin and ginseng berry extract; OVA+GB), animals were sacrificed 3 days later by cervical dislocation. Incubation was performed at room temperature for 20 minutes after removal of the spleen and addition of collagenase containing 2% bovine serum. After pelleting by centrifugation of isolated cells and addition of Histopaque 1077 (Sigma-Aldrich) after lysing the pellets, the pellets were obtained by centrifugation again at 1700 g. After adding fluorescently labeled antibodies that can recognize CD45.2, OT-I and OT-II and incubating for 30 minutes, followed by washing with FACS buffer, by using FlowJo (version 9.7.6) flow cytometry analysis by BD FACS LSR. It was found that the co-administered group of ginseng berry extract and ovalbumin exhibited enhanced proliferation of antigen-specific T cells compared to the group administered only ovalbumin (Fig. 5).

[Test Example 7] Inhibitory effect of ginseng berry extract on tumor

1×10 ⁶ melanoma cancer cells were injected into the C57BL/6 mice of Test Example 2. After waiting 7 days until the cancer cells settled and injecting intravenously twice at 5-day intervals PBS, 0.05 mg/kg ovalbumin (OVA) alone or 0.05 mg/kg ovalbumin and 50 mg/kg ginseng berry extract Tumor volume was analyzed after ovalbumin and ginseng berry extract; OVA+GB. It was found that the group co-administered with ginseng berry extract and ovalbumin significantly inhibited the proliferation of tumors compared to the group administered only ovalbumin (Figure 6).

Hereinafter, the present disclosure will be described in detail via formulation examples. However, the following formulation examples are for illustration purposes only, and the scope of the present disclosure is not limited by these examples.

[Formulation Example 1] Preparation of Pills

The ginseng berry extract prepared in the example 1 of 30wt%, the ovalbumin of 0.03wt%, the cornstarch of 30wt%, After the glycerin of 20wt% and the sorbitol powder of 20wt% are mixed, use pill machine to prepare pill. The final weight of the pellets was 3.5 g.

[Formulation Example 2] Preparation of Tablets

The ginseng berry extract prepared in the example 1 of 30wt%, the ovalbumin of 0.03wt%, the lactose of 20.5wt%, the dextrin of 20wt%, the maltitol powder of 20wt% and the xylitol powder of 7wt% were mixed and After granulation using a fluidized bed dryer, 2.5 wt% of sugar ester was added and lozenges were prepared using a tablet machine. The final weight of the lozenges is 2 g.

[Formulation Example 3] Preparation of Granules

After mixing 30 wt% of the ginseng berry extract prepared in Example 1, 0.03 wt% of ovalbumin, 5 wt% of xylitol, and 65 wt% of isomalt and granulated using a fluidized bed granulator, the resulting The prepared granules are filled in sachets. The final weight of the granules was 2 g.

[Formulation Example 4] Preparation of Injection

Injections were prepared using the compositions described in Table 4 according to common methods.

[Preparation Example 5] Preparation of Healthy Food

Health food was prepared using the compositions described in Table 5 according to common methods.

Claims (15)

A use of ginseng berry extract and ovalbumin in the manufacture of a composition for cancer immunotherapy, wherein the cancer is malignant melanoma, wherein the ginseng berry extract is an extract obtained by: using C ₁ - _C6 alcohol reflux extracts ginseng berry and concentrates under reduced pressure, wherein based on the total weight of the ginseng berry extract, the ginseng berry extract contains 0.1 to 10wt% of the following one or more: ginsenoside Rb1, ginsenoside Rb2 , ginsenoside Rb3, ginsenoside Rc, ginsenoside Rd, ginsenoside Rg1 and ginsenoside Rg2, wherein the ginseng berry extract has protopanaxadiol (protopanaxadiol; PD) ginsenoside and protopanaxatriol (protopanaxatriol; PT) The ratio of ginsenosides, PD/PT, is 0.50 to 2.5, wherein the concentration of the ginseng berry extract is 1 to 100 μg/mL, and wherein the concentration of ovalbumin is 0.001 to 0.1 μg/mL, and wherein the composition promotes bone marrow Proliferation of cells, activation of T cells, and activation of dendritic cells. The use according to claim 1, wherein the composition comprises 0.001 to 80.0wt% of the ginseng berry extract based on the total weight of the composition. The use as described in Claim 1, wherein the ginseng berry extract contains 8.0 to 30.0 wt% of ginsenoside Re based on the total weight of the ginseng berry extract. The use as described in Claim 1, wherein based on the total weight of the ginseng berry extract, the ginseng berry extract comprises 23 to 80 wt% of total ginsenosides. The use as described in claim 1, wherein the ginseng berry extract further contains vitamins, minerals and anthocyanins. The use as described in claim 5, wherein based on the total weight of the ginseng berry extract, the minerals include one or more of the following: 4000mg/100g or more of potassium, 600mg/100g or more of calcium, 40mg Iron per 100g or more, phosphorus at 150mg/100g or more, magnesium at 250mg/100g or more, and zinc at 140mg/100g or more. The use as described in claim 5, wherein based on the total weight of the ginseng berry extract, the vitamin comprises one or more of the following: 150 μg/100g or more of vitamin A, 8 mg/100g or more of vitamin _B1 , 5mg/100g or more vitamin B ₂ , 8mg/100g or more vitamin B ₆ , 3mg/100g or more vitamin C, 180μg/100g or more vitamin K, 3.5mg/100g or more niacin, 4mg/100g or more pantothenic acid and 250μg/100g or more folic acid. The use as described in claim 5, wherein the concentration of the anthocyanins is 20 ppm (w/w) or higher based on the total weight of the ginseng berry extract. The use as described in claim 5, wherein the anthocyanin comprises a compound selected from the group consisting of malvidin chloride, ideain chloride, pelargonidin chloride and chloride One or more of the group consisting of keracyanin chloride. The use as described in claim 9, wherein the ginseng berry extract comprises: based on the total weight of the ginseng berry extract, 8.0 to 16.0ppm (w/w) of chlorinated mallow pigment; Based on the total weight of the ginseng berry extract, 1.0 to 5.0 ppm (w/w) of chlorinated cyanidin galactoside; based on the total weight of the ginseng berry extract, 6.0 to 12.0 ppm (w/w) of chlorinated geranium; and Based on the total weight of the ginseng berry extract, 2.0 to 6.0 ppm (w/w) of chlorinated anthocyanidin rhamnoside. The use according to claim 1, wherein based on 100 parts by weight of the ginseng berry extract, the composition comprises 0.01 to 1 part by weight of ovalbumin. The use as described in claim 1, wherein the composition is a pharmaceutical composition. The use as described in Claim 1, wherein the composition is a health food composition. A cancer immunotherapy kit comprising: a composition comprising ovalbumin; a composition comprising a ginseng berry extract; and an instruction sheet, wherein the cancer is malignant melanoma, wherein the ginseng berry extract is an extract obtained by reflux extracting ginseng berries with C ₁ -C ₆ alcohol and concentrating under reduced pressure, wherein the ginseng berry extract contains 0.1 to 10 wt% based on the total weight of the ginseng berry extract One or more of the following: ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rc, ginsenoside Rd, ginsenoside Rg1 and ginsenoside Rg2, wherein the ginseng berry extract contains protopanaxadiol; A ratio of PD) ginsenosides to protopanaxatriol (protopanaxatriol; PT) ginsenosides, PD/PT, is 0.50 to 2.5, wherein the concentration of the ginseng berry extract is 1 to 100 μg/mL, wherein the concentration of ovalbumin is 0.001 to 0.1 μg/mL, wherein the dosage of the composition comprising ovalbumin is 0.001 to 0.1 mg/kg/day, and the dosage of the composition comprising ginseng berry extract is 1 to 100 mg/kg/day, wherein the composition comprising ginseng berry extract promotes proliferation of bone marrow cells and activation of T cells, and activates dendritic cells, and wherein the specification describes the composition comprising ovalbumin and the composition comprising ginseng berry extract Dosing at the same time. The kit according to claim 14, wherein the instructions describe a second administration of the composition comprising ovalbumin and the composition comprising ginseng berry extract 1 to 14 days after the first administration.

Images